Abstract
Recent findings in a clinical trial in which an adeno-associated virus (AAV) vector expressing coagulation factor IX (F.IX) was introduced into the liver of hemophilia B subjects highlighted a new issue previously not identified in animal studies. Upon AAV gene transfer to liver, two subjects enrolled in this trial developed transient elevation of liver enzymes, likely as a consequence of immune rejection of transduced hepatocytes mediated by AAV capsid-specific CD8+ T cells. Studies in healthy donors showed that humans carry a population of antigen-specific memory CD8+ T cells probably arising from wild-type AAV infections. The hypothesis formulated here is that these cells expanded upon re-exposure to capsid, i.e. upon AAV-2 hepatic gene transfer, and cleared AAV epitope-bearing transduced hepatocytes. Other hypotheses have been formulated which include specific receptor-binding properties of AAV-2 capsid, presence of capsidexpressing DNA in AAV vector preparations, and expression of alternative reading frames from the transgene. Absence of a valid animal model has prevented an in-depth mechanistic study of the phenomenon. Several possible solutions to the problem are discussed, including the administration of a short-term anti-T cell immunosuppression regimen concomitant with gene transfer. While more studies will be necessary to further define mechanisms and risks associated with capsidspecific immune responses in humans, monitoring of these responses in clinical trials will be essential to achieving the goal of long-term therapeutic gene transfer in humans.
Keywords: Adeno-associated virus, AAV, immune response, gene therapy, clinical trial, CD8 T cells, capsid, liver
Current Gene Therapy
Title: Immune Responses to AAV in Clinical Trials
Volume: 7 Issue: 5
Author(s): Federico Mingozzi and Katherine A. High
Affiliation:
Keywords: Adeno-associated virus, AAV, immune response, gene therapy, clinical trial, CD8 T cells, capsid, liver
Abstract: Recent findings in a clinical trial in which an adeno-associated virus (AAV) vector expressing coagulation factor IX (F.IX) was introduced into the liver of hemophilia B subjects highlighted a new issue previously not identified in animal studies. Upon AAV gene transfer to liver, two subjects enrolled in this trial developed transient elevation of liver enzymes, likely as a consequence of immune rejection of transduced hepatocytes mediated by AAV capsid-specific CD8+ T cells. Studies in healthy donors showed that humans carry a population of antigen-specific memory CD8+ T cells probably arising from wild-type AAV infections. The hypothesis formulated here is that these cells expanded upon re-exposure to capsid, i.e. upon AAV-2 hepatic gene transfer, and cleared AAV epitope-bearing transduced hepatocytes. Other hypotheses have been formulated which include specific receptor-binding properties of AAV-2 capsid, presence of capsidexpressing DNA in AAV vector preparations, and expression of alternative reading frames from the transgene. Absence of a valid animal model has prevented an in-depth mechanistic study of the phenomenon. Several possible solutions to the problem are discussed, including the administration of a short-term anti-T cell immunosuppression regimen concomitant with gene transfer. While more studies will be necessary to further define mechanisms and risks associated with capsidspecific immune responses in humans, monitoring of these responses in clinical trials will be essential to achieving the goal of long-term therapeutic gene transfer in humans.
Export Options
About this article
Cite this article as:
Mingozzi Federico and High A. Katherine, Immune Responses to AAV in Clinical Trials, Current Gene Therapy 2007; 7 (5) . https://dx.doi.org/10.2174/156652307782151425
DOI https://dx.doi.org/10.2174/156652307782151425 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Pathophysiology of Heme in the Brain
Current Alzheimer Research Editorial [Hot Topic: Pharmacological Treatments of Alcohol and Drug Addiction: Whats New? (Executive Guest Editor: Laurent Karila)]
Current Pharmaceutical Design A Systematic Review on Levosimendan in Paediatric Patients
Current Vascular Pharmacology Systemic Fungal Infections Caused by Candida Species: Epidemiology, Infection Process and Virulence Attributes
Current Drug Targets The Two Faces of Iminoalditols: Powerful Inhibitors Trigger Glycosidase Activation
Current Enzyme Inhibition Industrial Applications of Thermostable Enzymes from Extremophilic Microorganisms
Current Biochemical Engineering (Discontinued) Prognostic and Predictive Biomarkers in Cancer
Current Cancer Drug Targets Alterations of Sex Differentiation in Males: From Candidate Genes to Diagnosis and Treatments
Current Pharmaceutical Design C-Methionine PET/CT in Central Nervous System Tumours: A Review
Current Radiopharmaceuticals Past Efforts and Future Prospects for a Nasal Influenza Vaccine
Clinical Immunology, Endocrine & Metabolic Drugs (Discontinued) Fluoroquinolones in Pediatrics
Current Drug Therapy Impact of Early Life Stress on the Pathogenesis of Mental Disorders: Relation to Brain Oxidative Stress
Current Pharmaceutical Design Microaspiration in Intubated Critically Ill Patients: Diagnosis and Prevention
Infectious Disorders - Drug Targets Anti-Angiogenic and Anti-Inflammatory Effects of Statins: Relevance to Anti-Cancer Therapy
Current Cancer Drug Targets Cannabinoids as Neuroprotective Agents in Traumatic Brain Injury
Current Pharmaceutical Design Keeping the Balance Between Proliferation and Differentiation:The Primary Cilium
Current Genomics The Utility of Metformin Therapy in Reproductive-Aged Women with Polycystic Ovary Syndrome (PCOS)
Current Pharmaceutical Biotechnology Current View on the Mechanism of Action of Perifosine in Cancer
Anti-Cancer Agents in Medicinal Chemistry Policy and Adolescent Tobacco Use Prevention
Adolescent Psychiatry The Underestimated Role of Mechanical Stimuli in Brain Diseases and the Relate d In Vitro Models
Current Pharmaceutical Design